Last reviewed · How we verify
Micronutrient
Micronutrient is a Small molecule drug developed by University of California, San Francisco. It is currently in Phase 2 development.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Micronutrient |
|---|---|
| Sponsor | University of California, San Francisco |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Multiple Micronutrient Supplementation With Digital Layering Among Adolescents in Tanzania (NA)
- Phenylalanine-free Diet for Patients With Secondary Hyperphenylalaninemia in ICU (NA)
- Choline to Improve Malnutrition and Enhance Cognition (NA)
- Peanut-based School Meals in Rural Ghana to Improve Attendance and Retention (NA)
- Child Health, Agriculture and Integrated Nutrition (NA)
- Impact of CRRT on Serum Carnitine and Micronutrient Levels
- Effects of Complementary Feeding of Eggs on Infant Development and Growth in Guatemala: The Saqmolo Study (NA)
- Folic Acid Salt Study (FISFA Zambia) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Micronutrient CI brief — competitive landscape report
- Micronutrient updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI
Frequently asked questions about Micronutrient
What is Micronutrient?
Who makes Micronutrient?
What development phase is Micronutrient in?
Related
- Manufacturer: University of California, San Francisco — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing